TP101 drove near-complete tumor regression in mice. What must Tract Bio prove next?
Tract Bio's AACR posters link TP101 and stemECHO to drug-resistant cancer stem cells, while IND work and clinical validation remain the key hurdles ahead.
Pharma & Biotech